Bio-Techne Corp

+0.11 (+0.02%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)17.12B
Current PE93.17
Forward PE 67.43
2yr Forward PE 57.86
See more stats
Estimates Current Quarter
Revenue$244.52 Million
Adjusted EPS$1.70
See more estimates
10-Day MA$436.93
50-Day MA$421.07
200-Day MA$344.83
See more pivots

Bio-Techne Corp Stock, NASDAQ:TECH

614 McKinley Place NE, Minneapolis, Minnesota 55413-2610
United States of America
Phone: +1.612.379.2956
Number of Employees: 2300


Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.